DOP2012000269A - Combinaciones que contienen 2, 3-dihidroimidazo[1,2-c]quinazolina sustituida - Google Patents

Combinaciones que contienen 2, 3-dihidroimidazo[1,2-c]quinazolina sustituida

Info

Publication number
DOP2012000269A
DOP2012000269A DO2012000269A DO2012000269A DOP2012000269A DO P2012000269 A DOP2012000269 A DO P2012000269A DO 2012000269 A DO2012000269 A DO 2012000269A DO 2012000269 A DO2012000269 A DO 2012000269A DO P2012000269 A DOP2012000269 A DO P2012000269A
Authority
DO
Dominican Republic
Prior art keywords
component
dihydroimidazo
combinations
quinazoline
solvate
Prior art date
Application number
DO2012000269A
Other languages
English (en)
Spanish (es)
Inventor
Ningshu Liu
Original Assignee
Bayer Ip Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44144895&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DOP2012000269(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Ip Gmbh filed Critical Bayer Ip Gmbh
Publication of DOP2012000269A publication Critical patent/DOP2012000269A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DO2012000269A 2010-04-16 2012-10-16 Combinaciones que contienen 2, 3-dihidroimidazo[1,2-c]quinazolina sustituida DOP2012000269A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP10160109 2010-04-16

Publications (1)

Publication Number Publication Date
DOP2012000269A true DOP2012000269A (es) 2012-12-15

Family

ID=44144895

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2012000269A DOP2012000269A (es) 2010-04-16 2012-10-16 Combinaciones que contienen 2, 3-dihidroimidazo[1,2-c]quinazolina sustituida

Country Status (24)

Country Link
US (1) US20130184270A1 (enExample)
EP (1) EP2558126A2 (enExample)
JP (1) JP5886271B2 (enExample)
KR (1) KR20130098155A (enExample)
CN (1) CN102958540B (enExample)
AU (1) AU2011240003A1 (enExample)
BR (1) BR112012026480A2 (enExample)
CA (1) CA2796253A1 (enExample)
CL (1) CL2012002887A1 (enExample)
CO (1) CO6620036A2 (enExample)
CR (1) CR20120524A (enExample)
CU (1) CU20120150A7 (enExample)
DO (1) DOP2012000269A (enExample)
EA (1) EA201201414A8 (enExample)
EC (1) ECSP12012261A (enExample)
IL (1) IL222356A0 (enExample)
MA (1) MA34158B1 (enExample)
MX (1) MX2012012064A (enExample)
PE (1) PE20130191A1 (enExample)
PH (1) PH12012502069A1 (enExample)
SG (1) SG184550A1 (enExample)
TN (1) TN2012000493A1 (enExample)
WO (1) WO2011128407A2 (enExample)
ZA (1) ZA201208616B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2168583A1 (en) 2008-09-24 2010-03-31 Bayer Schering Pharma Aktiengesellschaft Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for the treatment of myeloma
UA113280C2 (xx) 2010-11-11 2017-01-10 АМІНОСПИРТЗАМІЩЕНІ ПОХІДНІ 2,3-ДИГІДРОІМІДАЗО$1,2-c]ХІНАЗОЛІНУ, ПРИДАТНІ ДЛЯ ЛІКУВАННЯ ГІПЕРПРОЛІФЕРАТИВНИХ ПОРУШЕНЬ І ЗАХВОРЮВАНЬ, ПОВ'ЯЗАНИХ З АНГІОГЕНЕЗОМ
JO3733B1 (ar) * 2011-04-05 2021-01-31 Bayer Ip Gmbh استخدام 3,2-دايهيدروايميدازو[1, 2 -c]كوينازولينات مستبدلة
EP2508525A1 (en) 2011-04-05 2012-10-10 Bayer Pharma Aktiengesellschaft Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts
WO2014160034A1 (en) * 2013-03-14 2014-10-02 The Board Of Trustees Of The Leland Stanford Junior University Aldehyde dehydrogenase-1 modulators and methods of use thereof
JP6368353B2 (ja) 2013-04-08 2018-08-01 バイエル ファーマ アクチエンゲゼルシャフト 置換された２，３−ジヒドロイミダゾ［１，２−ｃ］キナゾリン類のリンパ腫治療への使用
WO2015082376A2 (en) * 2013-12-03 2015-06-11 Bayer Pharma Aktiengesellschaft Use of pi3k-inhibitors
MX2017011607A (es) * 2015-03-09 2018-04-10 Bayer Pharma AG Uso de 2,3-dihidroimidazol[1,2-c]quinazolinas sustituidas.
US10406162B2 (en) * 2015-03-09 2019-09-10 Bayer Pharma Aktiengesellschaft Substituted 2,3-dihydroimidazo[1,2-C]quinazoline-containing combinations
CA3016584A1 (en) * 2016-03-08 2017-09-14 Bayer Pharma Aktiengesellschaft 2-amino-n-[7-methoxy-2,3-dihydroimidazo-[1,2-c]quinazolin-5-yl]pyrimidine-5-carboxamides
WO2019002068A1 (en) 2017-06-28 2019-01-03 Bayer Consumer Care Ag COMBINATION OF A PI3K INHIBITOR AND AN ANDROGEN RECEPTOR ANTAGONIST
EP3723754A4 (en) 2017-12-13 2021-05-19 Merck Sharp & Dohme Corp. IMIDAZO [1,2-C] QUINAZOLINE-5-AMINE COMPOUNDS WITH PROPERTIES OF A2A ANTAGONIST

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
KR101059652B1 (ko) 2002-09-30 2011-08-25 바이엘 파마 악티엔게젤샤프트 접합 아졸-피리미딘 유도체
JP4323793B2 (ja) 2002-12-16 2009-09-02 キヤノン株式会社 ズームレンズ及びそれを有する光学機器
DE102004064002B4 (de) 2004-08-04 2019-05-09 Continental Automotive Gmbh System zum Überwachen einer Sensorvorrichtung
US8101799B2 (en) * 2005-07-21 2012-01-24 Ardea Biosciences Derivatives of N-(arylamino) sulfonamides as inhibitors of MEK
PL1912636T3 (pl) 2005-07-21 2015-02-27 Ardea Biosciences Inc N-(aryloamino)sulfonamidowe inhibitory mek
AR064106A1 (es) 2006-12-05 2009-03-11 Bayer Schering Pharma Ag Derivados de 2,3-dihidroimidazo [1,2-c] quinazolina sustituida utiles para el tratamiento de enfermedades y trastornos hiper-proliferativos asociados con la angiogenesis
KR20110014149A (ko) * 2008-04-14 2011-02-10 아디아 바이오사이언스즈 인크. 조성물 및 이것의 제조 및 사용 방법
EP2168583A1 (en) * 2008-09-24 2010-03-31 Bayer Schering Pharma Aktiengesellschaft Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for the treatment of myeloma

Also Published As

Publication number Publication date
KR20130098155A (ko) 2013-09-04
WO2011128407A2 (en) 2011-10-20
WO2011128407A3 (en) 2012-02-23
AU2011240003A1 (en) 2012-11-08
TN2012000493A1 (en) 2014-04-01
US20130184270A1 (en) 2013-07-18
MA34158B1 (fr) 2013-04-03
MX2012012064A (es) 2012-12-17
SG184550A1 (en) 2012-11-29
EP2558126A2 (en) 2013-02-20
CA2796253A1 (en) 2011-10-20
CN102958540A (zh) 2013-03-06
CR20120524A (es) 2013-01-09
CN102958540B (zh) 2015-09-02
IL222356A0 (en) 2012-12-31
EA201201414A1 (ru) 2013-04-30
WO2011128407A9 (en) 2011-12-22
BR112012026480A2 (pt) 2016-08-16
CO6620036A2 (es) 2013-02-15
ZA201208616B (en) 2015-08-26
PH12012502069A1 (en) 2013-02-04
PE20130191A1 (es) 2013-02-21
HK1182937A1 (en) 2013-12-13
CL2012002887A1 (es) 2013-01-18
JP5886271B2 (ja) 2016-03-16
JP2013525293A (ja) 2013-06-20
ECSP12012261A (es) 2012-11-30
EA201201414A8 (ru) 2013-12-30
CU20120150A7 (es) 2013-02-26

Similar Documents

Publication Publication Date Title
DOP2012000269A (es) Combinaciones que contienen 2, 3-dihidroimidazo[1,2-c]quinazolina sustituida
CU20130050A7 (es) Combinaciones que contienen n-(2-arilamino) arilsulfonamida sustituida
SV2017005530A (es) Combinaciones que contienen 2,3- dihidroimidazo[1,2-c]quinazolina sustituida
NI201800051A (es) Compuestos de imidazo[4, 5-c]quinolin-2-ona y su uso en eltratamiento de cáncer
CO2018003969A2 (es) Compuestos de imidazo[4,5-c]quinolin-2-ona
ECSP088747A (es) Pirazoles como inhibidores de la 11-beta-hsd1
BR112015029512A2 (pt) derivados de pirazolopirrolidina e seu uso no tratamento de doenças
CO6630134A2 (es) Formulación orales y sales lipofílicas de metilnaltrexona
AR077464A1 (es) Terapia de combinacion para el tratamiento de la diabetes
AR054347A1 (es) Combinaciones terapeuticas para el tratamiento o la prevencion de la depresion
CO2018001700A2 (es) Derivados de n-[1h-bencimidazol-2-il] metil-pirazin-2-il-carboxamida, composiciones y procedimientos de preparación de los mismos
NI201900094A (es) COMPUESTOS DE TIPO IMIDAZO[4, 5-c]QUINOLIN-2-ONA DEUTERADOS Y SU USO EN EL TRATAMIENTO DEL CÁNCER
AR086800A1 (es) Composicion farmaceutica oftalmologica topica que contiene regorafenib
BR112015018200A2 (pt) composição mastigável para administração oral e processo para preparar a mesma
BR112016009214A8 (pt) uso de um composto para preparação de um medicamento para o tratamento de distrofia muscular e composição farmacêutica
BR112014030288A8 (pt) composição farmacêutica, uso da mesma, e, uso de metanossulfonilacetonitrila
BR112013025410A2 (pt) tratamento terapêutico
NO20092230L (no) Azabicykliske heterocykler som cannabinoid reseptor modulatorer
ECSP088237A (es) Derivados de quinolina y uso como agentes antitumor
TN2013000141A1 (en) Substituted n-(2-arylamino) aryl sulfonamide-containing combinations
BR112014001751A2 (pt) derivados de pirazolina e seu uso como moduladores seletivos do receptor de estrogênio
UY33806A (es) ?compuestos novedosos de imidazoquinolina, composiciones que los contienen y su uso en el tratamiento de enfermedades mediadas por tlr7?
BR112012028376B8 (pt) Derivado inusitado da síntese de ecdisterona, seu método de preparação e uso
AR072871A1 (es) Combinacion terapeutica que comprende un inhibidor de aurora quinasa y un agente antineoplasico, composicion farmaceutica